Business Wire

Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease

Share

Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.

The Series A was co-led by seed investor Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and incoming investor AbbVie, with further investment from the JDRF T1D Fund (the venture capital fund of JDRF) and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The €28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.

The Series A marks AbbVie’s first venture investment into an Italian company. Enthera was also the first European investment of the JDRF T1D fund, who previously invested in the Company during its €4 million seed extension funding round in 2018.

The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate. Ent001 is the only drug in development with the potential to restore the pancreatic beta cell compartment in type 1 diabetes as well as the original intestine structure in inflammatory bowel disease, in order to re-establish organ function. The funds will also be used to further develop Enthera’s pipeline.

Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: “Having renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund choosing to support us on our journey is great validation of our company strategy and scientific method, and gives credit to the innovative science that is currently underway in Italy.

“We have a revolutionary approach that offers a new perspective for intractable diseases such as type 1 diabetes and inflammatory bowel disease, and the funds raised will enable us to accelerate our lead program Ent001 to clinical proof-of-concept. Through this and the development of our wider pipeline, we have the opportunity to bring real hope to patients in need and to provide effective and safe treatments.”

Graziano Seghezzi, Managing Partner of Sofinnova Partners, who co-seeded the company, stated:
“Enthera’s Series A financing is a fantastic milestone enabled by the leadership of Giovanni who, since his arrival in the company, has expanded its activities into novel therapeutic areas. This is also an opportunity for us to applaud BiovelocITA’s role in transforming the breakthrough science originating from Paolo Fiorina and his team into a full-fledged enterprise. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class science, experienced management, and dedicated financial capital.”

Margarita Chavez, Managing Director of AbbVie Ventures and new addition to the Enthera Board of Directors, added: “AbbVie Ventures’ investment in Enthera’s Series A demonstrates our confidence in the team and their unique approach to treating underserved autoimmune disorders. I look forward to working with Giovanni and rest of the team as we drive the Company and its innovation forward.”

Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio. The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund. A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.

ENDS

Notes to Editors

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca D’Addio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Enthera’s discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

For more information, please visit: www.sofinnovapartners.com

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization.

For more information, please visit www.abbvie.com/ventures

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About the JDRF T1D Fund

The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance therapeutics, devices, diagnostics and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.

www.t1dfund.org

BiovelocITA

BiovelocITA S.r.l. is the first Italian accelerator dedicated to biotech. It was founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. Thanks to BiovelocITA, entrepreneurs, scientists and investors can work together to accelerate biotech projects with an international scope and reach the “proof of concept” that precedes the clinical phase. Set up to offer innovative solutions to the medical community and to patients, BiovelocITA supports the creation and development of innovative biotech companies in all therapeutic areas.

For more information, see: http://www.biovelocita.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:

Enthera Pharmaceuticals
Giovanni Amabile, CEO
T: +39 (0)2 3456778
E: info@entherapharmaceuticals.com

Instinctif Partners (media enquiries)
Dr Christelle Kerouedan / Siobhan Sanford / Kiki Zaccagnini
Tel: +44 20 7457 2020
E: enthera@instinctif.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vedanta Aluminium Becomes India’s Largest Green Power Purchaser5.8.2021 13:48:00 EEST | Press release

Vedanta Aluminium Business, India’s largest producer of aluminium and value-added products, became India’s largest green power purchaser at the Indian Energy Exchange Limited (IEX) in Q1 FY22. For its largest integrated aluminium production facility at Jharsuguda, in Odisha (India), Vedanta procured 354 million units of solar and non-solar renewable energy primarily from IEX’s Green Term-Ahead Market (GTAM). Purchase of green power from GTAM has enabled organisations like Vedanta to achieve their carbon-mitigation targets while producing ‘green’ value-added products. Vedanta Aluminium’s purchase of green power units is more than 35% of the green power traded on IEX in Q1 FY22. Speaking about Vedanta’s approach towards carbon mitigation, Mr. Rahul Sharma, CEO – Vedanta Aluminium Business said, “Our sustainability imperatives are designed to fulfil our climate impact reduction targets, which are in complete alignment with the goals of Paris Agreement and Nationally Determined Contributio

ISAE-SUPAERO Continues Its Involvement in the InSight Mission and Reveals the Results of Its Research From Planet Mars5.8.2021 11:24:00 EEST | Press release

Launched by NASA in May 2018, the InSight mission is pursuing the objective of studying the internal structure of the planet Mars using the SEIS seismometer developed by ISAE-SUPAERO. Three studies, published on July 23 in the journal Science, reveal, for the first time, an estimate of the size of the core, the thickness of the crust and the structure of the mantle of the red planet. Three of the co-authors, Raphaël Garcia, Mélanie Drilleau and Nicolas Compaire, are from ISAE-SUPAERO, and are collaborating on this major seismic exploration project, which represents a significant step in the understanding of the formation and thermal evolution of Mars. Before this mission, the internal structure of Mars was still poorly understood. The details of the planet's internal structure and the depth of the boundaries between crust, mantle and core were completely unknown. With the successful deployment of the SEIS experiment on the surface of Mars in early 2019, the scientists collected and ana

Yamaha Motor Earnings Continue to Rise in Second Quarter5.8.2021 11:12:00 EEST | Press release

Yamaha Motor Co., Ltd. (TOKYO:7272) announces its consolidated business results for the first half of fiscal 2021. Net sales for the consolidated accounting period for the first six months of the fiscal year ending December 31, 2021 were 920.1 billion yen (an increase of 234.6 billion yen or 34.2% compared with the same period of the previous fiscal year) and operating income was 109.2 billion yen (an increase of 90.1 billion yen or 471.9%). Ordinary income was 115.1 billion yen (an increase of 94.3 billion yen or 454.8%) and net income for the period attributable to owners of parent was 93.1 billion yen (compared to a quarterly net loss of 2.8 billion yen in the same period of the previous fiscal year). For net sales, the worldwide spread of COVID-19 infections since March last year led to lower unit sales and production numbers, but the impacts have diminished over this first half of the fiscal year and demand has recovered in all business segments, resulting in higher sales overall.

Nordic Enterprises Seek Help with Ransomware Schemes5.8.2021 11:00:00 EEST | Press release

Facing a dramatic rise in cyberattacks, enterprises in the Nordic countries are turning to cybersecurity services and solutions providers to thwart ransomware and other malicious intrusions, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™ Cybersecurity – Solutions & Services Report for the Nordics finds businesses in the region looking for support to keep cybercriminals from stealing intellectual property and personal information. Enterprises in the Nordics, including those in the healthcare, hospitality, IT and finance industries, saw a significant increase in cyberattacks in 2020. “High-profile cyberattacks in the Nordics point to growing efforts by international cybercriminals to disrupt businesses and cause harm,” said Roger Albrecht, co-leader of ISG Cybersecurity. “In the coming years, their main targets are likely to be banks, payment providers, insure

Altium Advances STEM Education with Expanded Curriculum and New Partnerships5.8.2021 10:00:00 EEST | Press release

In September 2020, Altium LLC, the leading printed circuit board (PCB) software company, launched Upverter Education, a free distance learning initiative to support STEM educators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005356/en/ Start your school year right with Upverter Education, an award-winning electronics design curriculum. (Photo: Altium LLC) The free Electronics Design Essentials program was designed for high school STEM teachers covering everything from engineering to robotics, with guided courses, certification and Upverter, an easy-to-use web-based tool for electronics design. Rea Callender, Vice President of Altium Education, elaborates, “Through Altium’s education initiatives, beginning with Upverter Education, we are introducing students of all ages to electronics design and sparking passion in people where they never knew it existed. You can’t have a passion for something if you don’t know it ex

Servify's Massive Growth Leads to Expansion of Global Team with Key Hires Across Business Domains5.8.2021 08:30:00 EEST | Press release

Servify, a leading provider of Extended Care and Product Protection solutions using its global, AI-enabled, digital platform, has announced hiring of senior leaders across regions and functions to drive its global expansion. Arun Verma, MS Kalsi, Kevin Cundiff, Edward Lee, Swetha Prashant, Peter Duesing, Sanghoon (Sam) Kwon, Hussein Hussein and Sergey Odinets have all been hired to bolster various verticals and regions within the organisation. Arun Verma, with more than 20 years of experience, was appointed as the Chief Human Resources Officer. He has championed impressive success in people management across distinctly diverse industries such as Technology & Services, Finance, Management Consulting & FMCG. He worked as CHRO and Head of Administration of Beetel before Servify, and with the likes of Xerox India, McKinsey & Co., Reliance Capital Limited, and CavinKare in the past. Makhan Singh Kalsi, also known as M S Kalsi, joins Servify as its Chief Service Officer after previously serv

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance15.8.2021 08:00:00 EEST | Press release

Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as COVID-19 restrictions eased in key markets. Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance. FINANCIAL PERFORMANCE2: CONTINUED OVERALL GROWTH Reported net sales of CHF 859.3 million, up 1.5% (up 5.0% at CER) EBITDA of CHF 281.0 million, up 0.2% (up 5.3% at CER). Excluding other income, EBITDA increased 9.4% (up 15.0% at CER) Other income of CHF 20.4 million, down 51.7% due to lower income from partnering and other activities Gross profit margin of 62.5%, up 1.4 percentage points driven by higher share of sales from the iron portfolio Net profit attributable to shareholders of Vifor Pharma Ltd. of CHF 124.4 million, driven by lower depreciation, amortization and impairment, as well as the strong net financial result in H1 2021 Strong ba

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom